Resources
- sort by:
- Relevance
- Date
- Popularity
- Brazil said Abbott Laboratories, a U.S. pharmaceutical company, has agreed to cut the price of its AIDS drug Kaletra sold in the country
- BRAZIL said Abbott Laboratories, a U.S. pharmaceutical company, has agreed to cut the price of its AIDS drug Kaletra sold in the country. The Brazilian government had threatened to break the patent should Abbott fail to lower prices. The government said the agreement will save the country US$259 million over...
- Research articles 2005-10-01
- Abbott Labs' "Position of Strength" May Not Be as Strong as It Looks
- Figuring out whether Abbott Laboratories is firing on all cylinders or heading for a wall is a complicated business. On the one hand, the company announced it would lay off 1,000 employees in its diagnostics business. Abbott spokesperson Melissa Brotz said: We are taking this action...
- Blog posts 2008-08-26
- Brazil signals may break patent on Abbot AIDS drug
- BRASILIA AFP — Brazilian Health Minister Humberto Costa signalled his government was set to move to break the patent on Abbot Laboratories' Kaletra AIDS drug because it would reduce treatment costs. Citing "public interest," Costa said the Brazilian government would likely break the patent on Kaletra, but that the...
- Research articles 2005-06-24
- Abbott Laboratories' Kaletra(TM) (lopinavir/ritonavir) Continues To Suppress HIV After Nearly Two Years in Patients New to HIV Therapy.
- TORONTO, Sep 17, 2000 TORONTO, Sep 17, 2000
- Research articles 2000-09-18
- Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir).
- ABBOTT PARK, Illinois, April 10 /PRNewswire/ -- ABBOTT PARK, Illinois, April 10 /PRNewswire/ --
- Research articles 2007-04-10
- Phase III Data Show More Patients Taking Abbott Laboratories' Kaletra(TM) (lopinavir/ritonavir) Regimen Achieved Undetectable Levels of HIV Than.
- TORONTO, Sep 18, 2000 TORONTO, Sep 18, 2000
- Research articles 2000-09-18
- Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients.
- ABBOTT PARK, Illinois, November 12 /PRNewswire/ -- ABBOTT PARK, Illinois, November 12 /PRNewswire/ --
- Research articles 2007-11-12
- Is There Really a "Market Price" for Drugs?
- Everyone seems to be ganging up on high drug prices these days. In two separate hearings last week, Congressional committees took after drugmakers for big markups on specialty treatments and a pharma "windfall" created by the Medicare prescription-drug benefit, while the WSJ took a hard look at the opacity of...
- Blog posts 2008-07-27
- Abbott Labs' Secret Weapon: Layoffs
- Sometimes a company does everything right and no one notices: Abbott Labs just unveiled a stellar third quarter and investors shrugged, leaving its stock flat. The basics you already know: Profit up 51 percent to $1.08 billion, sales up 17.6 percent to $7.5 billion. But check out...
- Blog posts 2008-10-15
- Heat-resistant HIV-AIDS drugs from US arrive Nigeria: MSF
- LAGOS AFP — Heat resistant anti-retroviral HIV-AIDS drugs manufactured in the United States have arrived in Nigeria, Africa's most populous country, Medecins Sans Frontiers Doctors Without Borders, said. The new version of the fixed-dose combination lopinavir/ritonavir (CPV/R), marketed as Kaletra by Abbott Laboratories, was approved for use last October....
- Research articles 2006-07-27
- Thailand in talks on cheaper AIDS drugs
- BANGKOK AFP — Thailand said it has opened talks with US drugmaker Abbott Laboratories on lowering the price of an AIDS treatment, which could avoid the need for a generic version Bangkok approved last week. Thailand has already issued a so-called "compulsory license" for the anti-AIDS drug Kaletra, which...
- Research articles 2007-02-08
- US drug maker offers Thailand further cuts on anti-AIDS drugs
- BANGKOK AFP — US drug maker Abbott on Monday offered to sell new anti-AIDS medicine at a cut price in Thailand, a senior health official said, in a bid to resolve a stand-off with Thailand over generic drugs. The government here has jolted the powerful pharmaceutical industry by allowing...
- Research articles 2007-05-14
- Lake County Briefs.(Business)
- Abbott wins European drug OK LIBERTYVILLE TOWNSHIP - Abbott Laboratories received tentative European approval for Kaletra, an AIDS treatment shown to be less toxic than an earlier version of the drug, Bloomberg News reported Monday. The drug was approved for use by adults and...
- Research articles 2000-12-19
- Abbott Labs Q1: Has the Company Taken Its Eye Off the Sales Force Ball?
- Abbott Labs' stock took a beating today even though it posted a 53 percent gain in net income, to $1.4 billion. Investors didn't like that $1 billion of that profit came from a one-off item reflecting the end of a joint venture with TAP. Revenues were flat at $6.7 billion....
- Blog posts 2009-04-15
- Abbott Q3: How a Monopoly Over an HIV Drug Resulted in Lower Sales
- A court decision recently put a stamp of approval on Abbott's monopoly over Norvir, a protease inhibitor that functions as a booster for its HIV drug, Kaletra. But that now-legal monopoly has not resulted in increased sales, according to Abbott's Q3 2009 earnings report. by Jim Edwards
- Blog posts 2009-10-14
- << Previous
- page 1 of 1
- Next >>
